论文部分内容阅读
Background The risk for development of CHD is 2-4 times higher in type 2 diabetes mellitus (T2DM) than in non-diabetics.Strategies capable of assessing changes in vascular endothelium at the preclinical stage hold potential to refine cardiovascular risk.MicroRNA-92a (miR-92a) was identified as an endogenous repressor of the angiogenic program in endothelial cells (ECs).This study focuses on the aberrant expression of miR-92a in patients with stable angina pectoris (SAP) and diabetes.